XTX Markets’s Rigel Pharmaceuticals RIGL Stock Holding History

XTX Markets’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,496	Closed	-$32K	–	135
2019 Q4	$32K	Buy	+1,496	New	+$30.8K	0.23%	67

Other funds holding RIGL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

XTX Markets's RIGL Position: Q1 2020 in Review

XTX Markets sold out of Rigel Pharmaceuticals (RIGL) in Q1 2020, closing a stake of 1,496 shares — an estimated $32K sold.

XTX Markets first reported a position in RIGL in Q4 2019 and held it in 1 quarter. The position peaked at $32K in Q4 2019. 126 funds tracked by Wall St. Rank hold RIGL as of Q1 2020.

XTX Markets reported no remaining Rigel Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
XTX Markets sold 1,496 Rigel Pharmaceuticals shares in Q1 2020, an estimated $32K.
XTX Markets first reported a position in Rigel Pharmaceuticals in Q4 2019 and held it in 1 quarter.
XTX Markets's Rigel Pharmaceuticals position peaked at $32K in Q4 2019.
126 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2020.

Based on XTX Markets's 13F filing for Q1 2020, filed 20 Apr 2020.